These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 19850631)

  • 1. A Mathematical Algorithm for Dried Blood Spot Quality Assessment and Results concerning Quality from a Newborn Screening Program.
    Oprea OR; Barabas AZ; Manescu IB; Dobreanu M
    J Appl Lab Med; 2024 May; 9(3):512-525. PubMed ID: 38384160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Pilot External Quality Assessment Scheme for Genetic Testing of Newborns with Spinal Muscular Atrophy.
    Wang W; Wu L; Hui Y; Du Y; Yang J; Jiang P; Gu M; He H; Qiu L; Zhang Z; Gao L; Lin C; Jiang J; He X; Miao J; Li Y; Luo Z; Zhang H; Liu Y; Li L; Li X; Gan X; Mou K; Liang H; Shi A; Zhou S; Huang X; Sun L; Wan T; Ji G; Tang K; Ye Q; Sun Z; Dai Z; Du Y; Wang X; Yang Y; Xiong H; Wang Z
    Clin Lab; 2024 May; 70(5):. PubMed ID: 38747911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix-matched calibrators are necessary for robust and high-quality dried blood spots lead screening assays by inductively coupled plasma-mass spectrometry.
    Franco JMC; Muldrow RA; Cieslak W; DeArmond P; Orahoske C; Payto D; Greene DN; Bunch D
    J Mass Spectrom Adv Clin Lab; 2023 Nov; 30():45-50. PubMed ID: 38023943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples.
    Laeremans H; Turner C; Andersson T; de Juan JAC; Gerrard A; Heiner-Fokkema MR; Herebian D; Janzen N; la Marca G; Rudebeck M
    JIMD Rep; 2020 May; 53(1):90-102. PubMed ID: 32395414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1.
    van Vliet K; Dijkstra AM; Bouva MJ; van der Krogt J; Bijsterveld K; van der Sluijs F; de Sain-van der Velden MG; Koop K; Rossi A; Thomas JA; Patera CA; Kiewiet MBG; Waters PJ; Cyr D; ; Boelen A; van Spronsen FJ; Heiner-Fokkema MR
    J Inherit Metab Dis; 2023 Nov; 46(6):1104-1113. PubMed ID: 37545091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with urinary succinylacetone-negative hereditary tyrosinemia type 1.
    Mori J; Furukawa T; Kodo K; Nakajima H; Yuasa M; Kubota M; Shigematsu Y
    Pediatr Int; 2023; 65(1):e15644. PubMed ID: 37795850
    [No Abstract]   [Full Text] [Related]  

  • 7. The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States.
    Adam BW; Hall EM; Sternberg M; Lim TH; Flores SR; O'Brien S; Simms D; Li LX; De Jesus VR; Hannon WH
    Clin Biochem; 2011 Dec; 44(17-18):1445-50. PubMed ID: 21963384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harmonizing Newborn Screening Laboratory Proficiency Test Results Using the CDC NSQAP Reference Materials.
    Pickens CA; Sternberg M; Seeterlin M; De Jesús VR; Morrissey M; Manning A; Bhakta S; Held PK; Mei J; Cuthbert C; Petritis K
    Int J Neonatal Screen; 2020 Sep; 6(3):75. PubMed ID: 33123642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening.
    Priestley JRC; Alharbi H; Callahan KP; Guzman H; Payan-Walters I; Smith L; Ficicioglu C; Ganetzky RD; Ahrens-Nicklas RC
    Int J Neonatal Screen; 2020 Jun; 6(2):. PubMed ID: 32832707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Newborn Screening Quality Assurance Program at the Centers for Disease Control and Prevention: Thirty-five Year Experience Assuring Newborn Screening Laboratory Quality.
    De Jesús VR; Mei JV; Cordovado SK; Cuthbert CD
    Int J Neonatal Screen; 2015; 1(1):13-26. PubMed ID: 26309908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking.
    Douglas CM; van El CG; Faulkner A; Cornel MC
    Croat Med J; 2012 Aug; 53(4):390-7. PubMed ID: 22911534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone.
    Dijkstra AM; Evers-van Vliet K; Heiner-Fokkema MR; Bodewes FAJA; Bos DK; Zsiros J; van Aerde KJ; Koop K; van Spronsen FJ; Lubout CMA
    Int J Neonatal Screen; 2023 Dec; 9(4):. PubMed ID: 38132825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders.
    Moat SJ; George RS; Carling RS
    Int J Neonatal Screen; 2020 Jun; 6(2):26. PubMed ID: 33073023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomic profiling suggests systemic signatures of premature aging induced by Hutchinson-Gilford progeria syndrome.
    Monnerat G; Evaristo GPC; Evaristo JAM; Dos Santos CGM; Carneiro G; Maciel L; Carvalho VO; Nogueira FCS; Domont GB; Campos de Carvalho AC
    Metabolomics; 2019 Jun; 15(7):100. PubMed ID: 31254107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
    Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
    Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
    De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
    Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential.
    la Marca G; Malvagia S; Pasquini E; Cavicchi C; Morrone A; Ciani F; Funghini S; Villanelli F; Zammarchi E; Guerrini R
    JIMD Rep; 2011; 1():107-9. PubMed ID: 23430836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of succinylacetone assays and their associated proficiency testing outcomes.
    Adam BW; Hall EM; Meredith NK; Lim TH; Haynes CA; De Jesus VR; Hannon WH
    Clin Biochem; 2012 Dec; 45(18):1658-63. PubMed ID: 22906829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I.
    Adam BW; Lim TH; Hall EM; Hannon WH
    Clin Chem; 2009 Dec; 55(12):2207-13. PubMed ID: 19850631
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.